New data out of the University of New Mexico suggest that the imaging agent’s physiologic reach may exceed what was previously believed.

New data suggest that it may not be necessary for women older than 65 with hormone receptor-positive breast cancer to undergo radiotherapy after breast-conserving surgery and hormone therapy, as it does not impact death rates or metastasis risk.

While the studies on these systems have proven them to be effective in diagnosing and treating COVID in specific cohorts, the varying settings in which they were used can make it difficult to derive definitive conclusions on their efficacy.

A new study utilizing multi-organ MRI scans recently identified organ impairment in 62% of COVID long haulers six months after their initial diagnosis; 29% of these individuals continued to display damage in at least one organ at the 12-month mark.

A new paper in the European Journal of Radiology offers an updated overview of common MRI findings in patients who develop foot drop following total hip arthroplasty.

Scans on these patients show a combination of fibrosis, thickening, honeycombing, cystic changes and dilation of the bronchi, among other imaging features.

A Feb. 14 announcement from Bracco indicates that the recently FDA-approved, gadolinium-based contrast agent VUEWAY, also known as gadopiclenol, is officially being used for patients undergoing MR imaging.

Once the go-to exam for gaining intra-articular details of major joints, MR arthrography appears to be wavering in popularity, decreasing 'drastically' at some institutions.